Veracyte Announces Global Expansion Plans with NanoString nCounter® Platform     Learn More
Veracyte Announces Global Expansion Plans with NanoString nCounter® Platform     Learn More
Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma
Agreement enabled by Veracyte acquisition of NanoString diagnostics assets for global expansion SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 8, 2020-- Veracyte (Nasdaq: VCYT) today announced a multi-year partnership with Acerta Pharma, the hematology research and development arm of
Toggle Summary Veracyte Acquires Exclusive License to NanoString Diagnostics Platform, Positioning Veracyte To Expand Its Genomic Testing Business Globally
Strategic transaction enables Veracyte to access global markets through a world-class, distributed instrument system, with an initial focus on its pulmonology franchise Provides pathway for long-term revenue growth and margin expansion Veracyte to hold conference call and webcast today at 5:30 p.m.


There are currently no events to display.


Title Documents

Corporate Presentation October 2019